Cargando…

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Targeting TP53 mutated myelodysplastic syndromes and acute myeloid leukemia remains a significant unmet need. Recently, new drugs have attempted to improve the outcomes of this poor molecular subgroup. The aim of this article is to review all the current knowledge using active agents including hypom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cluzeau, Thomas, Loschi, Michael, Fenaux, Pierre, Komrokji, Rami, Sallman, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471083/ https://www.ncbi.nlm.nih.gov/pubmed/34576266 http://dx.doi.org/10.3390/ijms221810105

Ejemplares similares

How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Loschi, Michael, et al.
Publicado: (2022)

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
por: Cluzeau, Thomas, et al.
Publicado: (2021)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Rahmé, Ramy, et al.
Publicado: (2023)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
por: Daver, Naval G., et al.
Publicado: (2022)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
por: Niparuck, Pimjai, et al.
Publicado: (2021)

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
por: Dutta, Sayantanee, et al.
Publicado: (2022)

Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
por: Maslah, Nabih, et al.
Publicado: (2020)

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
por: Haase, Detlef, et al.
Publicado: (2019)

TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology
por: Patel, Shyam A., et al.
Publicado: (2022)

Responses to Sars-Cov-2 Vaccines in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Jain, Akriti G, et al.
Publicado: (2021)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2021)

TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
por: Ok, Chi Young, et al.
Publicado: (2015)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2019)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes
por: McGraw, Kathy L., et al.
Publicado: (2015)

TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia
por: Testa, Ugo, et al.
Publicado: (2023)

U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes
por: Komrokji, Rami, et al.
Publicado: (2022)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions
por: Patel, Shyam A., et al.
Publicado: (2023)

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
por: Dutta, Sayantanee, et al.
Publicado: (2020)

IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy
por: Komrokji, Rami, et al.
Publicado: (2022)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
por: Mandhan, Nikeeta, et al.
Publicado: (2021)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Preexisting TP53 mutation in therapy-related acute myeloid leukemia
por: Schulz, Eduard, et al.
Publicado: (2014)

Clinical implications of subclonal TP53 mutations in acute myeloid leukemia
por: Prochazka, Katharina T., et al.
Publicado: (2019)

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
por: George, Binsah, et al.
Publicado: (2021)

TP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited
por: Shin, Dong-Yeop
Publicado: (2023)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
por: Bories, Pierre, et al.
Publicado: (2020)

TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings
por: Cumbo, Cosimo, et al.
Publicado: (2020)

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?
por: Molica, Matteo, et al.
Publicado: (2021)

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments
por: Granowicz, Eric M, et al.
Publicado: (2022)

Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
por: Shallis, Rory M., et al.
Publicado: (2022)

Rare Presentation of Acute Myeloid Leukemia With TP53 Mutation and Dermatologic Manifestations
por: Lott, Ronald, et al.
Publicado: (2023)

Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias
por: Testa, Ugo, et al.
Publicado: (2020)

Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)
por: Brunner, Andrew M., et al.
Publicado: (2022)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ijn6n9l5g9mqp93l54rarj7nfj